NovaBridge's Givastomig Could Drive A Major Re-Rating [Seeking Alpha]
NovaBridge Biosciences - American Depositary Shares (NBP)
Company Research
Source: Seeking Alpha
NBP's lead asset, Givastomig, has shown strong Phase 1b data—75% response rate, 16.9-month PFS, and manageable safety in gastric cancer. Upcoming 2026 Phase 1b data for Givastomig and a potential accelerated approval pathway are critical inflection points for re-rating. With $210.8M in cash, NBP has runway through 2028, supporting key clinical milestones for both Givastomig and VIS-101. FatCamera/E+ via Getty Images Thesis NovaBridge Biosciences ( NBP ) reported an FY25 GAAP EPS of about -$0.48. So, there have clearly been continued losses, with the company investing pretty heavily in clinical development. Now, even with the negative earnings, the company maintains a decent liquidity NBP's $210.8M in cash and short-term investments provides sufficient runway through 2028, materially reducing near-term financing risk even with elevated R&D spending. Updated Phase 1b data in 2026 and a potential FDA Type B meeting could enable accelerated approval and a Phase 3 registrati
Show less
Read more
Impact Snapshot
Event Time:
NBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBP alerts
High impacting NovaBridge Biosciences - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
NBP
News
- I-Mab (NBP) had its "buy" rating reaffirmed by HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- I-Mab Biopharma GAAP EPS of -$0.48 [Seeking Alpha]Seeking Alpha
- NovaBridge Reports Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Excalipoint debuts with $68.7m to progress TCE pipeline [Yahoo! Finance]Yahoo! Finance
NBP
Earnings
- 4/7/26 - Miss
NBP
Sec Filings
- 4/10/26 - Form 3/A
- 4/7/26 - Form 6-K
- 4/7/26 - Form 20-F
- NBP's page on the SEC website